Overdue Bilski Could Hold Clue
Madness to 'Method' Ruling? Time Will Tell in Myriad Case
By Randy Osborne
Monday, April 5, 2010
With last week's federal ruling that invalidated Myriad Genetics Inc.'s patent claims on BRCA1 and BRCA2 genes, all eyes are on the appeals court, even as pundits continue to speculate what an ultimate, irrevocable decision either way might mean.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.